Pfizer gets Swiss yes for Xeljanz amid EU delay
This article was originally published in Scrip
Executive Summary
Glossing over the April rejection by the CHMP of its potential blockbuster JAK inhibitor Xeljanz (tofacitinib citrate), Pfizer has announced its approval in Switzerland and several other markets for use in rheumatoid arthritis.